Bactroban (mupirocin calcium) Nasal Ointment, 2% 1g tube, Rx only, Manufactured by Glaxo Operatio...
FDA Drug Recall #D-1359-2015 — Class II — August 13, 2015
Recall Summary
| Recall Number | D-1359-2015 |
| Classification | Class II — Moderate risk |
| Date Initiated | August 13, 2015 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | GlaxoSmithKline, LLC. |
| Location | Zebulon, NC |
| Product Type | Drugs |
| Quantity | 88,489 tubes |
Product Description
Bactroban (mupirocin calcium) Nasal Ointment, 2% 1g tube, Rx only, Manufactured by Glaxo Operations UK Ltd, Harmire Road, Barnard Castle, UK for GlaxoSmithKline PO Box 1217 Zebulon, NC 27597-1217. NDC 0029-1526-11
Reason for Recall
Penicillin Cross Contamination and Presence of Foreign Substance. Product was contaminated with penicillin and foreign substances during manufacturing process.
Distribution Pattern
Nationwide and Puerto Rico
Lot / Code Information
Lot #: C704202, Exp 11/2016; Lot #: C706532, Exp 12/2016; Lot #: C713177, Exp 1/2017; Lot #: C716567, Exp 2/2017, Lot #: C720097, C720098, Exp 3/2017, Expanded to include: C720096, Exp. 2/2017.
Other Recalls from GlaxoSmithKline, LLC.
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-1360-2015 | Class II | Bactroban Ointment (mupirocin calcium), 2% 22g ... | Aug 13, 2015 |
| D-1361-2015 | Class II | Bactroban Cream (mupirocin calcium), 2%, a) 15g... | Aug 13, 2015 |
| D-1362-2015 | Class II | Mupirocin Calcium Cream, 2%, a) 15g tube (NDC 6... | Aug 13, 2015 |
| D-388-2014 | Class II | Sumatriptan Succinate Injection, 6 mg, 0.5 mL F... | Nov 6, 2013 |
| D-387-2014 | Class II | Imitrex STATdose System, Imitrex (sumatriptan s... | Nov 6, 2013 |
Frequently Asked Questions
Injectable drugs and eye drops must be completely free of microbial contamination because they bypass the body's natural defenses. A contaminated injectable can introduce bacteria or fungi directly into the bloodstream, potentially causing sepsis, meningitis, or localized infections — all of which can be life-threatening. Contamination of sterile products almost always results in a Class I recall. If you received an injectable drug from a recalled lot, contact your healthcare provider immediately, even if you feel well, as some infections can have delayed onset.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.